---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-117771"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:12:36.626144+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma shareholders approve internalization deal; all director nominees elected

## Summary
- Proposal 2 (Membership Interest Purchase Agreement internalization) approved with 440.5M For, 74K Against.
- All nine director nominees elected, including Pablo Legorreta, Henry Fernandez, Bonnie Bassler.
- Advisory say-on-pay (Proposal 7) passed with 403.2M For, 36.8M Against.
- Appointment of Ernst & Young as auditor ratified with 493.5M For, 116K Against.

## SEC filing metadata
- accession: 0001193125-25-117771
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312525117771/0001193125-25-117771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312525117771/d52049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-117771
- JSON: https://secwatch.observer/filing/0001193125-25-117771.json
- Plain text: https://secwatch.observer/filing/0001193125-25-117771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.